ORCID as entered in ROS

Select Publications
2003, Human Molecular Biology An Introduction to the Molecular Basis of Health and Disease, Cambridge University Press
,2003, medicine for examinations
,2006, 'Professionalism', in Problem-Based Medical Case Management, pp. 271 - 279
,1993, 'Chemotherapy for Node-Negative Breast Cancer', in Medical Radiology, Springer Berlin Heidelberg, pp. 43 - 56, http://dx.doi.org/10.1007/978-3-642-84593-2_6
,2024, 'Development and validation of a deep learning model for improving detection of nonmelanoma skin cancers treated with Mohs micrographic surgery', JAAD International, 14, pp. 39 - 47, http://dx.doi.org/10.1016/j.jdin.2023.10.007
,2023, 'Machine learning prediction of patient-reported outcomes associated with systemic therapy from medical records.', Journal of Clinical Oncology, 41, pp. e13564 - e13564, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e13564
,2023, 'Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial', Journal of Clinical Oncology, 41, pp. 2007 - 2019, http://dx.doi.org/10.1200/JCO.22.01134
,2023, 'Synonymous alterations of cancer-associated Trp53 CpG mutational hotspots cause fatal developmental jaw malocclusions but no tumors in knock-in mice', PLoS ONE, 18, http://dx.doi.org/10.1371/journal.pone.0284327
,2023, 'Can cancer go green? It’s up to us', Frontiers in Oncology, 13, http://dx.doi.org/10.3389/fonc.2023.1074091
,2023, 'To find fault is easy, to find no-fault is fair.', Future Healthc J, 10, pp. 85 - 89, http://dx.doi.org/10.7861/fhj.2022-0049
,2022, 'Development and Validation of a Machine Learning Approach Leveraging Real-World Clinical Narratives as a Predictor of Survival in Advanced Cancer', JCO clinical cancer informatics, 6, pp. e2200064, http://dx.doi.org/10.1200/CCI.22.00064
,2021, 'The secret identities of TMPRSS2: Fertility factor, virus trafficker, inflammation moderator, prostate protector and tumor suppressor', Tumor Biology, 43, pp. 159 - 176, http://dx.doi.org/10.3233/TUB-211502
,2021, '2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology', Journal of Oncology, 2021, http://dx.doi.org/10.1155/2021/9955456
,2021, 'How aging of the global population is changing oncology', ecancermedicalscience, 15, http://dx.doi.org/10.3332/ecancer.2021.ed119
,2020, 'Effective conservative management of locally advanced conjunctival melanoma using initial systemic therapy', Clinical and Experimental Ophthalmology, 48, pp. 402 - 404, http://dx.doi.org/10.1111/ceo.13691
,2020, 'A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer', Annals of Oncology, 31, pp. 257 - 265, http://dx.doi.org/10.1016/j.annonc.2019.10.025
,2019, 'Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer', Oncologist, 24, pp. e1102 - e1107, http://dx.doi.org/10.1634/theoncologist.2018-0613
,2019, 'Predicting survival in advanced cancers by applying machine learning to clinical narratives.', Journal of Global Oncology, 5, pp. 32 - 32, http://dx.doi.org/10.1200/jgo.2019.5.suppl.32
,2019, 'Beyond BCG: The approaching era of personalised bladder-sparing therapies for non-muscle-invasive urothelial cancers', Future Oncology, 15, pp. 409 - 420, http://dx.doi.org/10.2217/fon-2018-0565
,2019, 'Results of a Prospective Phase 2 Pilot Trial of 177 Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014
,2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099
,2018, 'Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.', N Engl J Med, 379, pp. 122 - 137, http://dx.doi.org/10.1056/NEJMoa1803164
,2018, 'Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer', New England Journal of Medicine, 378, pp. 1408 - 1418, http://dx.doi.org/10.1056/nejmoa1715546
,2018, 'Cancer care treatment outcome ontology: A novel computable ontology for profiling treatment outcomes in patients with solid tumors', JCO Clinical Cancer Informatics, 2018, pp. 1 - 14, http://dx.doi.org/10.1200/CCI.18.00026
,2017, 'TEPAPA: A novel in silico feature learning pipeline for mining prognostic and associative factors from text-based electronic medical records', Scientific Reports, 7, pp. 6918, http://dx.doi.org/10.1038/s41598-017-07111-0
,2017, 'Thyroid cancer in a patient with lynch syndrome – case report and literature review', Therapeutics and Clinical Risk Management, 13, pp. 915 - 918, http://dx.doi.org/10.2147/TCRM.S121812
,2017, 'Cancer and the omics revolution', Australian Family Physician, 46, pp. 189 - 193
,2017, 'Accuracy and prognostic significance of oncologists’ estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer', Annals of Oncology, 28, pp. v226 - v227, http://dx.doi.org/10.1093/annonc/mdx369.050
,2016, 'Be careful what you wish for', Medical Journal of Australia, 205, pp. 521 - 522.e1, http://dx.doi.org/10.5694/MJA16.00836
,2016, 'Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: A machine learning approach', BMC Cancer, 16, pp. 929, http://dx.doi.org/10.1186/s12885-016-2972-z
,2016, 'Damage-inducible intragenic demethylation of the human TP53 tumor suppressor gene is associated with transcription from an alternative intronic promoter', Molecular Carcinogenesis, 55, pp. 1940 - 1951, http://dx.doi.org/10.1002/mc.22441
,2015, 'Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.', N Engl J Med, 373, pp. 1814 - 1823, http://dx.doi.org/10.1056/NEJMoa1510016
,2015, 'Resolution of paraneoplastic immune thrombocytopenia following everolimus treatment for metastatic renal cell carcinoma', Internal Medicine Journal, 45, pp. 666 - 669, http://dx.doi.org/10.1111/imj.12779
,2015, 'A periodic table for cancer', Future Oncology, 11, pp. 785 - 800, http://dx.doi.org/10.2217/fon.14.315
,2015, 'Adjuvant Ovarian Suppression in Premenopausal Breast Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 372, pp. 436 - 446, http://dx.doi.org/10.1056/NEJMoa1412379
,2015, 'PERSONAL VIEW "By the way doctor, I've booked an African safari after my next chemo"', BMJ-BRITISH MEDICAL JOURNAL, 350, http://dx.doi.org/10.1136/bmj.g7822
,2015, '500P Dependence of fluorodeoxyglucose avidity on tumour size in non-small cell lung cancer', Annals of Oncology, 26, pp. ix153 - ix153, http://dx.doi.org/10.1093/annonc/mdv534.04
,2014, 'Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: Implications for tumor biology and adjuvant therapy', BMC Cancer, 14, http://dx.doi.org/10.1186/1471-2407-14-826
,2014, 'Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 371, pp. 107 - 118, http://dx.doi.org/10.1056/NEJMoa1404037
,2014, 'Comparison of cetuximab and bevacizumab as first-line treatment in KRAS wild type advanced colorectal cancer patients: a retrospective analysis', EUROPEAN JOURNAL OF CANCER, 50, pp. S12 - S12, http://dx.doi.org/10.1016/S0959-8049(14)70040-1
,2014, 'Papillomavirus-associated squamous skin cancers following transplant immunosuppression: One Notch closer to control', Cancer Treatment Reviews, 40, pp. 205 - 214, http://dx.doi.org/10.1016/j.ctrv.2013.08.005
,2014, 'Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma', Current Oncology, 21, http://dx.doi.org/10.3747/co.21.1661
,2014, 'Emerging strategies for therapeutic targeting of the tumour microenvironment', Cancer Forum, 38, pp. 133 - 137
,2014, 'Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: Results from a systematic review and meta-analysis', Prostate Cancer and Prostatic Diseases, 17, pp. 105 - 111, http://dx.doi.org/10.1038/pcan.2014.10
,2013, 'The unpluggable in pursuit of the undruggable: Tackling the dark matter of the cancer therapeutics universe', Frontiers in Oncology, 3 DEC, http://dx.doi.org/10.3389/fonc.2013.00304
,2013, 'Has discovery-based cancer research been a bust?', Clinical and Translational Oncology, 15, pp. 865 - 870, http://dx.doi.org/10.1007/s12094-013-1071-8
,2013, 'Conserved nonsense-prone CpG sites in apoptosis-regulatory genes: Conditional stop signs on the road to cell death', Evolutionary Bioinformatics, 2013, pp. 275 - 283, http://dx.doi.org/10.4137/EBO.S11759
,2013, 'Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis', Asian Pacific Journal of Cancer Prevention, 14, pp. 6585 - 6590, http://dx.doi.org/10.7314/APJCP.2013.14.11.6585
,2013, 'Complete Radiologic Response of Bulky Cerebral Metastases From Newly Diagnosed HER2-Positive Breast Cancer to Upfront Trastuzumab-Based Chemotherapy.', World J Oncol, 4, pp. 122 - 125, http://dx.doi.org/10.4021/wjon639w
,2013, 'Death in The New York Times: the price of fame is a faster flame', QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 106, pp. 517 - 521, http://dx.doi.org/10.1093/qjmed/hct077
,